Search results
Showing 31 to 45 of 131 results for hepatitis
Evidence-based recommendations on Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C.
Introducing a blood borne virus testing facility within a substance misuse harm reduction service
A project to introduce hepatitis and HIV blood borne virus testing in a needle exchange and drug treatment
for hepatitis B and C be improved? What modifiable factors influence whether or not specific groups at increased risk of...
This guideline covers diagnosing and managing drug allergy in all age groups. It aims to make it easier for professionals to tell when someone is having an allergic reaction, by specifying the key signs and patterns to look out for. It also makes recommendations on improving people’s understanding of their drug allergies, and ensuring these are recorded properly in their medical records.
uptake of hepatitis C treatment be improved? What factors influence whether or not specific groups at increased risk will begin and...
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)
Evidence-based recommendations on rituximab for treating relapsed or refractory chronic lymphocytic leukaemia in adults.
View recommendations for TA193Show all sections
Question Long-term safety of tenofovir disoproxil in chronic hepatitis B:- Further research should be undertaken to determine the...
Collaborating with community pharmacists to deliver sexual health services
Hepatitis B and C testing: people at risk of infection
This guideline covers diagnosing and treating fertility problems. It aims to reduce variation in practice and improve the way fertility problems are investigated and managed.
This guideline covers needle and syringe programmes for people (including those under 16) who inject drugs. The main aim is to reduce the transmission of viruses and other infections caused by sharing injecting equipment, such as HIV, hepatitis B and C. In turn, this will reduce the prevalence of blood-borne viruses and bacterial infections, so benefiting wider society.
and cost effectiveness of hepatitis B surface antigen (HBsAg) quantitative assays in determining treatment duration in...
This quality standard covers assessing, diagnosing and managing physical health problems of adults aged 18 years and older in prisons or young offender institutes. It describes high-quality care in priority areas for improvement.
View quality statements for QS156Show all sections
Sections for QS156
- Quality statements
- Quality statement 1: Medicines reconciliation
- Quality statement 2: Second-stage health assessment
- Quality statement 3: Blood-borne viruses and sexually transmitted infections
- Quality statement 4: Lead care coordinator
- Quality statement 5: Medicines on transfer or discharge
- Update information
- About this quality standard
risk in awareness-raising about, and promoting testing and treatment for, hepatitis B and C infection? Specifically, how cost effective...
ensure continuity of care for prisoners who are diagnosed with chronic hepatitis B or C in prison? Any explanatory notes(if applicable)...
Question How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come...